Halasi Marianna, Váraljai Renáta, Benevolenskaya Elizaveta, Gartel Andrei L
From the Departments of Medicine and.
Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, Illinois 60612.
J Biol Chem. 2016 Jan 1;291(1):142-8. doi: 10.1074/jbc.M115.678227. Epub 2015 Nov 11.
The oncogenic transcription factor FOXM1 is overexpressed in the majority of human cancers, and it is a potential target for anticancer therapy. We identified proteasome inhibitors as the first type of drugs that target FOXM1 in cancer cells. Here we found that HSP90 inhibitor PF-4942847 and heat shock also suppress FOXM1. The common effector, which was induced after treatment with proteasome and HSP90 inhibitors or heat shock, was the molecular chaperone HSP70. We show that HSP70 binds to FOXM1 following proteotoxic stress and that HSP70 inhibits FOXM1 DNA-binding ability. Inhibition of FOXM1 transcriptional autoregulation by HSP70 leads to the suppression of FOXM1 protein expression. In addition, HSP70 suppression elevates FOXM1 expression, and simultaneous inhibition of FOXM1 and HSP70 increases the sensitivity of human cancer cells to anticancer drug-induced apoptosis. Overall, we determined the unique and novel mechanism of FOXM1 suppression by proteasome inhibitors.
致癌转录因子FOXM1在大多数人类癌症中过度表达,是抗癌治疗的潜在靶点。我们确定蛋白酶体抑制剂是癌细胞中靶向FOXM1的第一类药物。在此我们发现HSP90抑制剂PF-4942847和热休克也能抑制FOXM1。蛋白酶体和HSP90抑制剂或热休克处理后诱导产生的共同效应物是分子伴侣HSP70。我们表明,在蛋白毒性应激后HSP70与FOXM1结合,并且HSP70抑制FOXM1的DNA结合能力。HSP70对FOXM1转录自调控的抑制导致FOXM1蛋白表达的抑制。此外,HSP70的抑制会提高FOXM1的表达,同时抑制FOXM1和HSP70会增加人类癌细胞对抗癌药物诱导凋亡的敏感性。总体而言,我们确定了蛋白酶体抑制剂抑制FOXM1的独特且新颖的机制。